 |
 |
 |
Clay B. Siegall, Ph.D. President and Chief Executive Officer |
Clay Siegall co-founded Seattle Genetics in 1998 and is the company's President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based therapies to address unmet medical needs of cancer patients. In August 2011, Seattle Genetics' first commercial product, ADCETRIS™ (brentuximab vedotin), was granted accelerated approval by the U.S. Food and Drug Administration (FDA). ADCETRIS is one of more than a dozen antibody-drug conjugates (ADCs) in clinical development using Seattle Genetics' proprietary, industry-leading ADC technology, including three additional internal programs and several collaborator programs.
Dr. Siegall has also guided Seattle Genetics’ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Seattle Genetics has entered into multiple strategic collaborations, including with Millennium: The Takeda Oncology Company, Genentech (Roche), Bayer, Agensys (Astellas), Pfizer and Abbott.
Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals, a private biotechnology company. Dr. Siegall is an author on more than 70 publications and holds 15 patents. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.
 |
Eric L. Dobmeier Chief Operating Officer |
Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications, process sciences, technical operations and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Millennium: The Takeda Oncology Company for brentuximab vedotin (SGN-35) and ten ADC collaborations with leading biotechnology and pharmaceutical companies. He has also participated in raising more than $600 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier received a law degree from University of California, Berkeley and an undergraduate degree from Princeton University.
 |
Thomas C. Reynolds, M.D., Ph.D. Chief Medical Officer |
Tom Reynolds joined Seattle Genetics in March 2007. As Chief Medical Officer, he leads clinical and regulatory activities across the company's product portfolio. Dr. Reynolds has more than 15 years of biotechnology drug development experience, from preclinical development through the FDA approval process. Before joining Seattle Genetics, he was at Zymogenetics from 2002 to 2007, most recently as Vice President, Medical Affairs, where he oversaw the clinical development and BLA filing of rhThrombin and led the medical affairs department. Previously, he held various positions at Targeted Genetics including Vice President, Clinical Affairs, and before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds holds a B.A. in Chemistry from Dartmouth College and both a Ph.D. in Biophysics and M.D. from Stanford University.
 |
Todd E. Simpson Chief Financial Officer |
Todd Simpson joined Seattle Genetics in October 2005, bringing extensive industry experience from senior financial positions with several public biotechnology companies. Prior to joining Seattle Genetics, he served as Vice President of Finance and Administration and Chief Financial Officer at Targeted Genetics since October 2001. Previously, he was Vice President, Finance and Administration and Chief Financial Officer of Aastrom Biosciences. From 1992 to 1996, he served in financial roles at Integra Life Sciences Corporation and Telios Pharmaceuticals, Inc. (which was acquired by Integra in 1995). Mr. Simpson practiced public accounting with the firm of Ernst & Young LLP from 1983 to 1992, primarily focused in the life sciences and technology practices. He serves on the Board of the Washington Biotechnology and Biomedical Association (WBBA). Mr. Simpson is a certified public accountant and received his B.S. in Accounting and Computer Science from Oregon State University.
 |
Vaughn B. Himes, Ph.D. Executive Vice President, Technical Operations |
Vaughn Himes joined Seattle Genetics in April 2009, bringing more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. As Executive Vice President, Technical Operations, he oversees Seattle Genetics' manufacturing, supply chain and quality assurance and control functions. Previously, Dr. Himes was with Zymogenetics, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. While at Zymogenetics, he oversaw the chemistry, manufacturing and control (CMC) portion of the successful BLA for Recothrom and managed its commercial supply. Previously, he held Vice President positions in manufacturing and development at Corixa, Targeted Genetics and Genovo. Dr. Himes received a B.A. in Chemistry from Pomona College and a Ph.D. in Chemical Engineering from the University of Minnesota.
 |
Morris Z. Rosenberg, D.Sc. Executive Vice President, Process Sciences |
Morris Rosenberg joined Seattle Genetics in July 2001 and was named Executive Vice President, Process Sciences in February 2009. Since joining the company, Dr. Rosenberg has overseen significant growth of the company's development organization, including the process development, quality assurance and control, analytical biochemistry, formulation and manufacturing functions. Prior to joining Seattle Genetics, he was with Eli Lilly from 1998 to 2001 where, as Head of Cell Culture and Fermentation Development, he led efforts in the development of several cell culture processes including for the sepsis therapeutic Xigris. Before that, he was at Biogen (now Biogen Idec) where he participated in development of the manufacturing process for Avonex, a multiple sclerosis treatment. Dr. Rosenberg received a D.Sc. in Chemical Engineering, an M.S. and B.S. in Chemical Engineering, and a B.A. in Biology from Washington University in St. Louis.
 |
Bruce J. Seeley Executive Vice President, Commercial |
Bruce Seeley joined Seattle Genetics in October 2009 with more than 18 years of experience in oncology drug marketing and sales. As EVP, Commercial, Mr. Seeley will build and oversee Seattle Genetics’ marketing and sales functions as the company prepares for planned commercial operations. He previously worked at Genentech (a member of the Roche Group), most recently as Senior Director for Herceptin (trastuzumab) and T-DM1 marketing. His responsibilities included development and implementation of marketing and launch strategies, including product differentiation, pricing, distribution, medical education and promotion. Before that, Mr. Seeley spent four years at Aventis Pharma in increasing roles of responsibility, including Head of New Product Commercialization and Licensing, Global Marketing, Oncology. While at Aventis, he managed the global marketing activities for Taxotere (docetaxel). Mr. Seeley also held various marketing and sales positions at Rhone-Poulenc Rorer and Bristol-Myers Squibb. He received a B.A. in Sociology from the University of California at Los Angeles.
 |
Jonathan Drachman, M.D. Senior Vice President, Research and Translational Medicine |
Jonathan Drachman joined Seattle Genetics in November 2004. He oversees the company's research, preclinical and early clinical development activities. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. He also served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington.
 |
Christopher Pawlowicz Senior Vice President, Human Resources |
Christopher Pawlowicz joined Seattle Genetics in September 2008. He has more than 25 years of human resources experience principally in the pharmaceutical industry. Prior to Seattle Genetics, Mr. Pawlowicz was Senior Vice President, Human Resources and Administration at MedPointe Pharmaceuticals, a private equity-backed specialty pharma company where he was part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals. Before that, he was Corporate Vice President, Human Resources at Express Scripts, the nation's third largest pharmacy benefit management company. Mr. Pawlowicz's career has also included senior human resources positions at Pharmacia, Searle and Monsanto. Highlights include the global launch of Celebrex, the start up of biotechnology commercial teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and the post-merger integration of numerous companies. He graduated summa cum laude with a B.A. in Economics from Benedictine College, and received his M.A., Labor and Industrial Relations from the University of Illinois at Urbana-Champaign.
 |
Elaine Waller, Pharm.D. Senior Vice President, Regulatory Affairs |
Elaine Waller, Pharm.D., joined Seattle Genetics in September 2008, bringing more than 20 years of experience in regulatory affairs and clinical research. Prior to joining Seattle Genetics, Dr. Waller was with Sonus Pharmaceuticals, where she served as Senior Vice President, Regulatory Affairs/Quality Assurance and Clinical Research until its merger with OncoGenex Pharmaceuticals in August 2008. Before that, she was Chief Operating Officer at Radiant Research, a clinical site management organization. Dr. Waller's previous experience includes senior positions in regulatory affairs and clinical research at Hoechst Marion Roussel and Marion Merrell Dow, predecessor companies to sanofi-aventis. She began her career in academia at the University of Texas at Austin where she held teaching positions in both graduate and undergraduate pharmacy education and was Assistant Director of Clinical Research at the Drug Dynamics Institute. Dr. Waller received a B.S. in Pharmacy and a Doctor of Pharmacy from the University of Missouri-Kansas City and an M.B.A. from Rockhurst College.
 |
james kyle bryan, m.d.
Vice President, Medical Affairs |
James Kyle Bryan joined Seattle Genetics in October 2011. Dr. Bryan is a hematologist and medical oncologist, and brings more than 18 years of experience in oncology drug development. Prior to joining Seattle Genetics, Dr. Bryan was at PPD, Inc., a global contract research organization. He served most recently as Vice President of Global Product Development, working within a group of PPD medical specialists providing internal and external strategic consulting services. In this role he was the head of the therapeutic group for all hematology- and oncology-based services. Prior to joining PPD, Dr. Bryan was Director of Clinical Research at NeoRx Corporation (now Poniard Pharmaceuticals), a biotechnology company based in Seattle. In addition to his industry experience, Dr. Bryan was in the private practice of hematology and medical oncology and is currently a member of the teaching faculty at the University of Washington Medical Center. Dr. Bryan received a B.S. in Biochemistry and an M.D. from Louisiana State University and did his fellowship in hematology and oncology at the University of Washington.
 |
chris boerner, PH.D.
Vice President, Marketing |
Chris Boerner joined Seattle Genetics in December 2010. He has broad experience in oncology product marketing, including pre-launch planning and on-market commercialization. Prior to Seattle Genetics, Dr. Boerner spent more than eight years at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin and Director of Avastin franchise management. Additionally, he served in a variety of marketing roles across multiple disease areas, including immunology and lymphoma. Dr. Boerner joined Genentech from McKinsey & Company, a global strategic management consulting firm. He most recently was Vice President of Marketing at Dendreon. Dr. Boerner received his Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley, and holds an A.B. in Economics and History from Washington University in St. Louis.
 |
darren cline
Vice President, Managed Markets |
Darren Cline joined Seattle Genetics in December 2010, bringing more than 20 years of sales and marketing experience, including senior managed markets roles in leading biotechnology and pharmaceutical companies. He served most recently as Vice President, Market Access at Intermune, where he was responsible for obtaining managed markets access and coverage for the anticipated launch of pirfenidone. Prior to Intermune, Mr. Cline served for three years as Executive Director of Sales at Alexion, where he played an integral role in the successful launch of Soliris (eculizumab) in the United States. Before that, he spent more than 10 years at Amgen in sales, marketing and managed markets leadership positions. Mr. Cline received a B.S. degree in Marketing from San Diego State University and an M.B.A. from Pepperdine University.
 |
NATASHA HERNDAY
Vice President, Corporate Development |
Natasha Hernday joined Seattle Genetics in January 2011. She has broad experience in business and corporate development including in-licensing, out-licensing, venture capital and mergers and acquisitions. Prior to Seattle Genetics, Ms. Hernday spent more than 16 years at Amgen, building her career with roles in research, research project management and business development finance before joining the corporate development group. While in corporate development, Ms. Hernday was a senior member of the mergers and acquisitions team for approximately seven years, followed by two years building and leading Amgen's out-licensing efforts. Ms. Hernday received a B.A. in Biology from University of California Santa Barbara and an M.B.A. from Pepperdine University.
 |
Charles R. Romp Vice President, Sales |
Charles Romp joined Seattle Genetics in May 2010, bringing more than 19 years of biotechnology and pharmaceutical sales and sales management experience to the company. Since 1998, Mr. Romp was at Genentech, a member of the Roche Group, most recently as National Sales Director for Avastin (bevacizumab). During his tenure, he held several senior sales leadership positions for both oncology and immunology products, including Rituxan (rituximab) and Xolair (omalizumab), and was project lead for deployment recommendations for Genentech’s BioOncology sales forces. Previously, he was a Product Manager at GE Medical Systems (formerly Marquette Medical Systems), and before that he was a pharmaceutical sales representative, most recently at Sankyo Park Davis and GlaxoSmithKline. Mr. Romp received a B.A. from the University of Florida and an M.B.A. from Saint Leo University (formerly Saint Leo College) in Florida.
 |
Kirk D. Schumacher Vice President, Legal Affairs & Compliance and General Counsel |
Kirk Schumacher joined Seattle Genetics in October 2003 and oversees all aspects of the company’s legal affairs and corporate compliance. Since joining Seattle Genetics, he has participated in the negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization collaboration with Millennium: The Takeda Oncology Company for brentuximab vedotin (SGN-35), as well as ADC technology collaborations with Celldex Therapeutics, Progenics, Bayer, Daiichi Sankyo, Millennium and Agensys. He has also participated in equity financings for Seattle Genetics, first as outside legal advisor and then as internal corporate counsel. Prior to joining the company, Mr. Schumacher was with the law firms of Venture Law Group and Riddell Williams, where he represented technology companies, including Seattle Genetics, in connection with public and private financings, SEC compliance and reporting, mergers and acquisitions and corporate partnering and licensing transactions. Mr. Schumacher received his J.D. from Columbia Law School and a B.A. from the University of Wisconsin.
 |
Peter D. Senter, Ph.D. Vice President, Chemistry and Distinguished Fellow |
Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr. Senter was recognized as the company's first Distinguished Fellow. He leads Seattle Genetics' chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Senter received a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He is the Senior Editor of Bioconjugate Chemistry and serves on the Editorial Board of four scientific journals. Dr. Senter is an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 100 scientific publications and holds more than 20 patents.
 |
eric sievers, m.d.
Vice President, Clinical Affairs |
Eric Sievers joined Seattle Genetics in July 2006. He is responsible for directing, planning and executing clinical development activities for brentuximab vedotin. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for more than a decade. His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia by defining the safety and efficacy of Mylotarg (gemtuzumab ozogamicin) and evaluating novel flow cytometric techniques to predict leukemic recurrence. Dr. Sievers received both a B.A. in Biology and an M.D. from Brown University. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research and the European Hematology Association, and is certified by the American Board of Pediatrics.
 |
charles smith
Vice President, Quality |
Charles Smith joined Seattle Genetics in 2003 and has served as Vice President, Quality since September 2011. Since joining Seattle Genetics, Mr. Smith has established the quality assurance (QA) function and oversight for all good manufacturing practices (GMP), good laboratory practices (GLP) and good clinical practices (GCP) activities and led the development of the quality control (QC) laboratory function. He has also contributed to the preparation of the chemistry, manufacturing and controls (CMC) sections for multiple regulatory submissions. Prior to joining Seattle Genetics, Mr. Smith spent seven years at Targeted Genetics, most recently as Senior Director of Quality Control. Before that, he spent 11 years at Genentech in increasing roles of responsibility, including Manager of Quality Control Clinical Development. Mr. Smith received his B.A in Molecular and Cellular Genetics from Humboldt State University and holds the CQA certifications for Quality Engineer and Quality Auditor.